Promising new rabies vaccine passes phase 3 test

NCT ID NCT03965962

Completed Prevention Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tested a new rabies vaccine (VRVg-2) in 640 healthy adults in France. Participants received the vaccine along with rabies immune globulin, mimicking a real post-exposure scenario. The study found that VRVg-2 produced protective antibody levels as effectively as two existing rabies vaccines. The results suggest VRVg-2 could be a safe and effective option for preventing rabies after exposure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Purified Vero Rabies Vaccine - Serum Free (VRVg-2)
What this could lead to: If successful, this could provide a new, safe, and effective rabies vaccine option for people exposed to the virus.
What could go wrong: This trial was completed in healthy adults in France, so results may not apply to everyone. Rabies is rare in developed countries, and the vaccine's performance in real-world exposure settings may differ.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RABIES (HEALTHY VOLUNTEERS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rabies prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RABIES (HEALTHY VOLUNTEERS)

Contacts and locations

Locations

Investigational Site Number 2500001

Rennes, 35000, France
Investigational Site Number 2500002

Gières, 38610, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.